Literature DB >> 23934402

Systemic lupus erythematosus (SLE) in the eastern region of Saudi Arabia. A comparative study.

N Abid1, A Sattar Khan, F Huzam Al Otaibi.   

Abstract

This retrospective study aimed to collect data related to the clinical manifestations and laboratory investigations of systemic lupus erythematosus (SLE) patients in the eastern part of Saudi Arabia, in one of the tertiary-care centers, King Fahd Hospital Al-Hasa, and to compare it with other regions of Saudi Arabia. Forty-six patients fulfilling the American College of Rheumatology 1997 criteria (ACR) were collected over a period from January 2004 to December 2008. The results showed an average age of onset of 26.17 (±9.17). The most common clinical features were nonspecific constitutional symptoms (fever, fatigue and malaise) seen in 44 patients (95.7%). Musculoskeletal features seen were mostly arthralgias (91.3%) and arthritis (76.1%). Nephritis was seen in 58.7% and hypertension in 52.2%. Mucocutaneous involvement included oral ulcers (71.7%), hair loss (65.2%), butterfly rashes (67.4%), photosensitivity (47.8%) and discoid lupus (13%). Neurologic manifestations showed psychosis in 17.4%, depression in 15.2% and headache in 28.3%. The most common hematologic presentation was leukopenia (58.7%) followed by hemolytic anemia and anemia of chronic disease (47.8%). Antinuclear antibodies were positive in 44 (95.7%), anti-dsDNA in 38 (42.6%), anti-Ro SSA and La SSB in 38 (82.6%). Anticardiolipin antibodies and lupus anticoagulant were positive in eight (17.4%). Low complement levels (C3 and C4) were seen in 41 (89.1%) of the patients with active disease. The drugs used in treatment were NSAIDs (100%), antimalarials (97.8%), steroids (100%), intermittent cyclophosphamide and other immunosuppressive drugs (71.7%). We found that the age of onset and sex distributions were different from other areas of Saudi Arabia, while clinical manifestations were the same as in other areas. The prognosis of lupus was good overall despite the multi-organ involvement. However, further studies based on larger number of patients are needed.

Entities:  

Keywords:  SLE; Saudi Arabia; lupus

Mesh:

Substances:

Year:  2013        PMID: 23934402     DOI: 10.1177/0961203313500548

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  6 in total

1.  Chinese SLE treatment and research group registry: III. association of autoantibodies with clinical manifestations in Chinese patients with systemic lupus erythematosus.

Authors:  Jing Li; Xiaomei Leng; Zhijun Li; Zhizhong Ye; Caifeng Li; Xiaofeng Li; Ping Zhu; Zhengang Wang; Yi Zheng; Xiangpei Li; Miaojia Zhang; Xin-Ping Tian; Mengtao Li; Jiuliang Zhao; Feng-Chun Zhang; Yan Zhao; Xiaofeng Zeng
Journal:  J Immunol Res       Date:  2014-04-23       Impact factor: 4.818

2.  Oral Manifestations of Systemic Lupus Erythematosus Patients in Qatar: A Pilot Study.

Authors:  Mohammed Hammoudeh; Ahmed Al-Momani; Husam Sarakbi; Prem Chandra; Samer Hammoudeh
Journal:  Int J Rheumatol       Date:  2018-04-10

3.  From Symptoms to Diagnosis: An Observational Study of the Journey of SLE Patients in Saudi Arabia.

Authors:  Mishal F Karremah; Rola Y Hassan; Ammar Z Faloudah; Lujain K Alharbi; Albraa F Shodari; Ahmad A Rahbeeni; Nouf K Alharazi; Ahmad Z Binjabi; Mohamed M Cheikh; Hanadi Manasfi; Sultana Abdulaziz; Albadr Hamza Hussein; Ahmed Alhazmi; Hani Almoallim
Journal:  Open Access Rheumatol       Date:  2022-06-29

4.  Glomerulonephritis disease pattern at Saudi tertiary care center.

Authors:  Khalid I AlMatham; Ali F AlFayez; Raghdah A AlHarthi; Falah S AlMutairi; Fahad S Alrasheedi; Abdulrehman Mustafa; Mustafa Ahmed; Basim A AlMatouq; Fadil A AlRowaei
Journal:  Saudi Med J       Date:  2017-11       Impact factor: 1.484

5.  Glomerulonephritis disease pattern at Saudi tertiary care center.

Authors:  Suzan M Attar
Journal:  Saudi Med J       Date:  2018-07       Impact factor: 1.484

Review 6.  An Overview of the Intrinsic Role of Citrullination in Autoimmune Disorders.

Authors:  Mohammed Alghamdi; Doaa Alasmari; Amjad Assiri; Ehab Mattar; Abdullah A Aljaddawi; Sana G Alattas; Elrashdy M Redwan
Journal:  J Immunol Res       Date:  2019-11-25       Impact factor: 4.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.